Process characterisation enables a thorough understanding of your manufacturing processes while establishing a controlled production system. Learn what is needed to establish process characterisation within biologics manufacturing. • Facilitating speed to market for biologics • Assessing potential risks and solutions when scaling up development • Considerations for developing a robust and scalable manufacturing process • Machine learning applications for improving current manufacturing protocols

Biologics manufacturing can be a complex and timely process when producing therapeutic proteins, antibodies, vaccines, and other large-molecule drugs. Gain insight into acceleration strategies for biologics manufacturing and how to meet the growing demand for biologics manufacturing. • Reviewing time-saving strategies to improve early-stage development processes • Assessing current upstream and downstream toolkits and how to best utilize them to drive efficiencies • Why defining your regulatory strategy can help improve manufacturing timelines

The global contract research, development and manufacturing (CRDMO) industry is in its next phase of evolution. Increased investments due to the COVID-19 pandemic along with the looming energy crisis and the on-going supply chain issues have had a major impact on the pharmaceutical industry. To remain competitive, companies are implementing innovative manufacturing strategies and prioritizing manufacturing efficiency. This is set to positively impact the CDMO industry wherein companies are employing differential service offerings and unique business models across drug discovery & development. This briefing charts the growth avenues for the CRDMO market in 2023 and beyond.

Advancing standards in biosimilar engineering encompass the ongoing efforts to establish rigorous criteria and guidelines for the development, characterisation, and manufacturing of biosimilars. Join for an understanding of what can be done to improve engineering standards in biosimilars, such as: • Why clearer regulations from both the FDA and EMEA can help progress manufacturing outcomes • Why having clear communication lines with patient organizations can help improve clinical outcomes • Reviewing cost measures to increase scalable manufacturing operations

• Where are all the approvals? Understanding unique manufacturing challenges for Autologous Cell Therapies
• How does development by design, quality by design, and Cell Therapy COGs converge in this new space?
• Creating a Cell Therapy technology roadmap to address challenges and drive speed-to-market